Drug Profile
Research programme: cell therapy - HemoGenyx
Alternative Names: Hu PHEC expanded; Hu PHEC liver; Hu PHEC UmbilicalLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Hemogenyx
- Developer Cornell University; Hemogenyx
- Class Antineoplastics; Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Aplastic anaemia; Haematological disorders
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Aplastic-anaemia in United Kingdom (Parenteral)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Haematological-disorders in United Kingdom (Parenteral)
- 30 Oct 2017 Hemogenyx has patents pending for Hu PHEC Liver (Hemogenyx website, October 2017) before October 2017